RxDoctor Payments Data

Fernando Velazquez-Arroyo, MD

Internal Medicine · Caguas, PRNPI 1861501918

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 50 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$285
  • Sanofi-aventis U.S. LLC$179
  • AstraZeneca$166
  • Olympus Latin America, Inc.$81
  • Medtronic$72
  • PBG Puerto Rico LLC$72
  • plus $229 from 7 others

What the payments were for

  • Food & beverage$1,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim11$285
Sanofi-aventis U.S. LLC11$179
AstraZeneca9$166
Olympus Latin America, Inc.1$81
Medtronic1$72
PBG Puerto Rico LLC3$72
GSK4$63
Johnson & Johnson2$48
Merck3$45
Pfizer Pharmaceuticals LLC2$27
AbbVie1$20
Novartis1$16
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$11

How this compares

$1,083 in reported general payments places this provider in the 60th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,983
Medicare patients
17
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban105$119,123
FarxigaDapagliflozin Propanediol109$116,388
EliquisApixaban101$94,877
CopaxoneGlatiramer Acetate13$75,816
SynthroidLevothyroxine Sodium618$75,223
Trijardy XrEmpaglifloz/Linaglip/Metformin38$43,857
OzempicSemaglutide35$43,293
JanumetSitagliptin Phos/Metformin Hcl31$42,614
JardianceEmpagliflozin20$33,473
MounjaroTirzepatide16$27,459
EntrestoSacubitril/Valsartan25$25,212
LantusInsulin Glargine,hum.Rec.Anlog126$22,337
JanuviaSitagliptin Phosphate12$21,053
TradjentaLinagliptin12$18,604
Sucralfate95$16,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Brilinta$166$138,112177 claims
Johnson & JohnsonXarelto$48$119,123105 claims
Boehringer IngelheimTrijardy Xr, Jardiance, Tradjenta, Jentadueto$285$111,42393 claims
AbbVieSynthroid, Restasis$20$80,684629 claims
MerckJanumet, Januvia$45$63,66643 claims
NovartisEntresto$16$25,21225 claims
Sanofi-aventis U.S. LLCLantus$179$22,337126 claims
GSKBreo Ellipta, Trelegy Ellipta$63$17,72936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →